Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes

Phernambucq, Erik C.J.; Hartemink, Koen J.; Smit, Egbert F.; Paul, Marinus A.; Postmus, Pieter E.; Comans, Emile F.I.; Senan, Suresh

doi:10.1097/jto.0b013e3182582912

Cited by 25 publications

(20 citation statements)

References 22 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cavitated tumours were observed in 26 (21%) of our patients, in line with previously reported rates ranging from 10% (baseline) to 20% (cancer treatment) [24,25]. In our series, only two patients suffering from adenocarcinoma exhibited cavitated tumours [25]. In view of the reported severe haemoptysis rates under anti-angiogenic therapy (0.7-2%), and as half of our patients exhibited SCC, it was not unexpected that none of our patients had undergone anti-angiogenic therapy [13,22].…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Severe haemoptysis in patients with nonsmall cell lung carcinoma

et al. 2014

View full text Add to dashboard Cite

Severe haemoptysis due to nonsmall cell lung cancer (NSCLC) is considered a grim condition, and there is still scarce data on its characteristics and outcome, despite new imaging and treatment modalities. This retrospective study sought to describe the clinical characteristics, pathophysiology and outcome of NSCLC-related haemoptysis.We included 125 consecutive patients with severe haemoptysis (>100 mL) at admission, 65 (52%) exhibiting squamous cell carcinoma. Tumour cavitation/necrosis was reported in 26 (21%) patients. 52 patients had received anticancer treatment, but none had received anti-angiogenic agents.Severe haemoptysis was related mainly to the bronchial artery (82%), and major pulmonary artery involvement was rare (6.4%). Interventional radiology was performed in 102 patients. Bleeding cessation was achieved in 108 (87%) out of 125 patients. The overall in-hospital and 1-year survival rates were 69% and 30%, respectively. Performance status (PS) ⩾2 (OR 3.6, 95% CI 1.3-9.6), advanced stage (OR 8.6, 95% CI 2-37) and mechanical ventilation (OR 13, 95% CI 4.5-36) were independent predictors of in-hospital mortality. Performance status ⩾2 (hazard ratio (HR) 2.4, 95% CI 1.5-3.7), advanced stage (HR 4, 95% CI 2.1-7.7), cancer progression (HR 2, 95% CI 1.01-2.7) and cavitation/necrosis (HR 1.7, 95% CI 1.21-3.2) were independently associated with 1-year mortality.Management of severe haemoptysis related to NSCLC should be improved, given our observed survival rates after hospital discharge. @ERSpublications NSCLC-related haemoptysis should not be considered dismissively; its management is still suboptimal

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionsupporting

confidence: 77%

Severe haemoptysis in patients with nonsmall cell lung carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Tumor cavitation has been reported as well. In one study, two out of 71 patients with stage III NSCLC undergoing CCRT developed de-novo cavitation [6] . There are increasing reports of NSCLC fistulization following CCRT, especially when using anti-angiogenic targeted therapy like Bevacizumab [7] , [8] , [9] , [10] .…”

Section: Discussionmentioning

confidence: 99%

Tracheo-parenchymal fistula following concurrent chemo-radiation for stage III NSCLC

Alzghoul

Meena

2016

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Non-Small Cell Cancer (NSCLC) are frequently diagnosed at a later stage [1]. Treatment involves chemotherapy and radiation, either sequentially or concurrently [2]. Concurrent therapy is more efficacious but also associated with more complications [4–6]. We present a rare care of trachea-pulmonary fistula formation after concurrent chemo and radiation in a patient with Squamous Cell Cancer (SCC).

show abstract

“…Treatment of infected necrosis in an irradiated area is difficult. 4 Surgical resection of the complete area is risky because of the scarring and patients usually present in a poor general condition. A less hazardous procedure to open the cavity and evacuate the necrotic and infected tissue is preferable.…”

Section: Commentmentioning

confidence: 99%

Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection

Schook

Smit

Postmus

et al. 2012

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes

Abstract: With CCRT, acute pulmonary toxicity of grade III or more developed in 50% of patients with stage III NSCLC, who also had radiological features of tumor cavitation. The optimal treatment of patients with this presentation is unclear given the high risk of a tumor abscess.

Cited by 25 publications

References 22 publications

Severe haemoptysis in patients with nonsmall cell lung carcinoma

Severe haemoptysis in patients with nonsmall cell lung carcinoma

Tracheo-parenchymal fistula following concurrent chemo-radiation for stage III NSCLC

Benefit of a Second Opinion for Lung Cancer: No Recurrent Disease, but Infection

Contact Info

Product

Resources

About